Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...
Cure Today17h
Learning to Live with Advanced Non-Small Cell Lung Cancer
Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include: ...